MyHealthChecked PLC
("MyHealthChecked" or the "Company")
Notice of results
MyHealthChecked PLC (AIM: MHC), the consumer home-testing healthcare company, will announce its interim results for the six months ended 30 June 2024 on Thursday 26 September 2024.
Penny McCormick, Chief Executive Officer, will provide a video update relating to the interim results which will be available to view on the day via the Company website and the Investor Meet Company platform. Investors can register for the Investor Meet Company platform and to receive notifications about MyHealthChecked PLC here: https://www.investormeetcompany.com/myhealthchecked-plc/register-investor
For further information contact:
| MyHealthChecked plc | |||
| Penny McCormick, Chief Executive Officer | via Walbrook PR | ||
| | | ||
| SPARK Advisory Partners Limited (NOMAD) | Tel: +44 (0)20 3368 3550 | ||
| Neil Baldwin / Jade Bayat | | ||
| | | ||
| Dowgate Capital Limited (Broker) | Tel: +44 (0)20 3903 7715 | ||
| David Poutney / Nicholas Chambers | | ||
| | | ||
| Walbrook PR Ltd (Media & IR) | Tel: +44 (0)20 7933 8780 or myhealthcheckedplc@walbrookpr.com | ||
| Paul McManus / Alice Woodings | Mob: +44 (0)7980 541 893 / +44(0)7407 804 654 | ||
About MyHealthChecked PLC (www.myhealthcheckedplc.com)
MyHealthChecked PLC, based in Cardiff, is an AIM-quoted pioneering UK healthcare company focused on a range of at-home healthcare and wellness tests.
MyHealthChecked is the umbrella brand of a range of at-home rapid tests, as well as DNA, RNA and blood sample collection kits which have been created to support customers on their journeys to wellness. The tests are lateral-flow self-tests, whilst the sample collection kits enable the collection of blood, urine, nasal or mouth swab samples that are analysed in partner laboratories for a range of biomarkers. The tests have been made available online and for over-the-counter purchase.
The MyHealthChecked portfolio has been identified as part of a change in mindset as customers become more familiar with the concept of accessible healthcare in the growing at home testing kit market with a focus on accessibility at the right price, led by UK-based experts.
RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
